Vexus-guided Fluid Management in Patients With Septic Shock After the Resuscitation Phase
Launched by FEDERAL UNIVERSITY OF SÃO PAULO · Jan 18, 2024
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to manage fluid levels in critically ill patients who are experiencing septic shock after their initial treatment. Septic shock is a serious condition where the body reacts strongly to infection, leading to low blood pressure and potential organ failure. In this trial, researchers want to find out if using a special ultrasound technique called VExUS can help guide doctors in deciding how much fluid to give or remove from patients, compared to the usual treatment methods. They believe that better fluid management might improve patient outcomes.
To participate in the trial, individuals must be over 18 years old, have been in the intensive care unit (ICU) for at least 48 hours, and have been stable in septic shock for at least 24 hours. Participants will be chosen randomly to either receive VExUS-guided fluid management or standard therapy. If eligible, patients can expect careful monitoring and tailored treatment during their ICU stay. The trial is not yet recruiting participants, but it aims to help improve care for patients with septic shock in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age over 18 years old.
- • Hospitalization in ICU for at least 48 hours.
- • Patient in septic shock for at least 24 hours and clinically stable defined by mean arterial pressure ≥ 65 mmHg and maximum infusion of 0.20 μg/kg/min of norepinephrine and lactate \< 4.0 mmol/L.
- • Signed informed consent
- Exclusion Criteria:
- • Patients in use of more than one vasopressor
- • Known right ventricle dysfunction
- • Indication to use furosemide for other reasons
- • Hypernatremia (Na \>160 mmol/L)
- • Advanced acute kidney injury(KDIGO 3)
- • Current renal replacement therapy
- • Anuria for ≥ 6 hours
- • Hepatorenal syndrome
- • Patients in palliative care
- • Furosemide allergy.
- • Rhabdomyolysis.
- • Major burn
About Federal University Of São Paulo
The Federal University of São Paulo (Universidade Federal de São Paulo - UNIFESP) is a prestigious institution dedicated to advancing education, research, and healthcare in Brazil. Renowned for its commitment to innovation and excellence, UNIFESP plays a pivotal role in clinical research, focusing on a multidisciplinary approach to improve health outcomes. The university fosters collaboration among researchers, healthcare professionals, and community stakeholders, ensuring that clinical trials conducted under its auspices adhere to rigorous ethical standards and contribute valuable insights to the medical field. With a rich history of academic achievement and a strong emphasis on translational research, UNIFESP is a key player in the development of new therapies and medical interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Flavia Machado
Principal Investigator
Federal University of São Paulo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported